Incorporating new technologies into the real-life classification of AML to guide treatment decisions

Maria Teresa Voso, MD, University Tor Vergata, Rome, Italy, discusses the challenge of incorporating new technologies, such as next-generation sequencing (NGS), into the real-life classification of acute myeloid leukemia (AML). She highlights that accurate classification can guide treatment decisions, such as using IDH-targeted therapies for patients with IDH mutations. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.